Relative Risk of Pulmonary Embolism and Deep Vein Thrombosis in Association with the Factor V Leiden Mutation in a United Kingdom Population

• References

• 1 Manten B, Westendorp R, Koster T, Reitsma P, Rosendaal F. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation. Thromb Haemost 1996; 76: 510-513
• 2 Baglin T, Baglin C, Brown K, Luddington R. and the East Anglian Thrombophilia Study Group The East Anglian Thrombophilia Study (First Phase): provisional report of thrombosis risk in the factor V Leiden (Q506) cohort. Brit J Haem 1996; 93 28 A105
• 3 Beauchamp N, Daly M, Hampton K, Cooper P, Preston F, Peake I. High prevalence of a mutation in the factor V gene within the UK population: Relationship to activated protein C resistance and familial thrombosis. Brit J Haem 1994; 88: 219-222
• 4 Luddington R, Brown K, Baglin T. Effect of platelet phospholipid exposure on activated protein C resistance: implications for thrombophilia screening. Brit J Haem 1996; 92: 744-746
• 5 Rees D, Cox M, Clegg J. World distribution of factor V Leiden. Lancet 1995; 346: 1133-1134
• 6 Koster T, Rosendaal F, de Ronde H, Briët E, Vandenbroucke J, Bertina R. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-1506
• 7 Svensson P, Dahlbäck B. Resistance to activated proteion C as a basis for venous thrombosis. New Eng J Med 1994; 330: 517-522
• 8 Zöller B, Svensson P, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. Journal of Clinical Investigation 1994; 94: 2521-2524